Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115689563 | 11568956 | 3 | F | 20150211 | 20160812 | 20150929 | 20160817 | EXP | US-009507513-1509USA011692 | MERCK | 14.00 | YR | F | Y | 53.00000 | KG | 20160817 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115689563 | 11568956 | 1 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 25 MG/M2, OVER 1-15 MIN ON DAYS 4 AND 5 IN A CYCLE OF 21 DAYS, IN CYCLES 2, 4 AND 6. | U | 0 | 25 | MG/M**2 | INJECTION | ||||||
| 115689563 | 11568956 | 2 | PS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 5 MG/M2, QD ON DAYS 1-2(PROPHASE) IN A CYCLE OF 5 DAYS | U | 12675 | 5 | MG/M**2 | TABLET | ||||||
| 115689563 | 11568956 | 3 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 5 MG/M2 BID ON DAYS 3-5 IN A CYCLE OF 5 DAYS (PROPHASE) | U | 12675 | 5 | MG/M**2 | TABLET | ||||||
| 115689563 | 11568956 | 4 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 5 MG/M2, BID ON DAYS 1-5 IN A CYCLE OF 21 DAYS | U | 12675 | 5 | MG/M**2 | TABLET | ||||||
| 115689563 | 11568956 | 5 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intrathecal | 7.5-12 MG, ON DAY 1(AGE BASED DOSING) ON PROPHASE IN A CYCLE OF 5 DAYS | U | 0 | |||||||||
| 115689563 | 11568956 | 6 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 3000 MG/M2 IV OVER 3 HOURS ON DAY 1 IN A CYCLE OF 21 DAYS | U | 0 | |||||||||
| 115689563 | 11568956 | 7 | SS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | 165 MG/M2, BID ON DAYS 1-21 | U | 0 | 165 | MG/M**2 | |||||||
| 115689563 | 11568956 | 8 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 200 MG/M2, OVER 15-30 MINS ON DAYS 1 AND 2(PROPHASE) IN A CYCLE OF 5 DAYS | U | 0 | 200 | MG/M**2 | |||||||
| 115689563 | 11568956 | 9 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 200 MG/M2, OVER 15-30 MINS ON DAYS 1-5 IN A CYCLE OF 21 DAYS, IN CYCLES 2, 4 AND 6 | U | 0 | 200 | MG/M**2 | |||||||
| 115689563 | 11568956 | 10 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | 100 MG/M2,OVER 2 HOURS ON DAYS 4 AND 5 IN COURSE A IN A CYCLE OF 21 DAYS, IN CYCLES 1, 3 AND 5. | U | 0 | 100 | MG/M**2 | |||||||
| 115689563 | 11568956 | 11 | C | CYTARABINE. | CYTARABINE | 1 | Intrathecal | 15-24MG, ON DAY 1 IN A CYCLE OF 5 DAYS (AGE BASED DOSING) | U | 0 | |||||||||
| 115689563 | 11568956 | 12 | C | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | 150 MG/M2, OVER 1-30 MINS Q12 HOURS ON DAYS 4 AND 5 IN A CYCLE OF 21 DAYS (TOTAL 4 DOSES) | U | 0 | 150 | MG/M**2 | |||||||
| 115689563 | 11568956 | 13 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | Intrathecal | 7.5-12 MG ON DAY 1 IN A CYCLE OF 5 DAYS(AGE BASED DOSING) | U | 0 | INJECTION | ||||||||
| 115689563 | 11568956 | 14 | C | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 800 MG/M2, OVER 60 MINS ON DAYS 1-5 IN A CYCLE OF 21 DAYS, IN CYCLES 1, 3 AND 5 | U | 0 | 800 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115689563 | 11568956 | 1 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 2 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 5 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 7 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 8 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 10 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 11 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 13 | Anaplastic large cell lymphoma T- and null-cell types |
| 115689563 | 11568956 | 14 | Anaplastic large cell lymphoma T- and null-cell types |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115689563 | 11568956 | OT |
| 115689563 | 11568956 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115689563 | 11568956 | Anaemia | |
| 115689563 | 11568956 | Hypokalaemia | |
| 115689563 | 11568956 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 115689563 | 11568956 | 1 | 20150201 | 0 | ||
| 115689563 | 11568956 | 2 | 20141007 | 0 | ||
| 115689563 | 11568956 | 4 | 20150201 | 0 | ||
| 115689563 | 11568956 | 5 | 20141007 | 0 | ||
| 115689563 | 11568956 | 6 | 20150128 | 0 | ||
| 115689563 | 11568956 | 7 | 20141007 | 20150211 | 0 | |
| 115689563 | 11568956 | 8 | 20141007 | 0 | ||
| 115689563 | 11568956 | 9 | 20150201 | 0 | ||
| 115689563 | 11568956 | 10 | 20150112 | 0 | ||
| 115689563 | 11568956 | 11 | 20141004 | 0 | ||
| 115689563 | 11568956 | 12 | 20150112 | 0 | ||
| 115689563 | 11568956 | 13 | 20141007 | 0 | ||
| 115689563 | 11568956 | 14 | 20141007 | 20150111 | 0 |